Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. - Wikidata - awgldk - TriplyDB

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

http://www.wikidata.org/entity/Q41775778

about

Current role of image-guided robotic radiosurgery (Cyberknife(®) ) for prostate cancer treatment Low temperature plasma: a novel focal therapy for localized prostate cancer?The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial.A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.Cancer and radiation therapy: current advances and future directions.Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study.Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Accuracy of marketing claims by providers of stereotactic radiation therapy.Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.Hypofractionated external-beam radiotherapy for prostate cancer.Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer.Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma Image guided hypofractionated radiotherapy by helical tomotherapy for prostate carcinoma: toxicity and impact on Nadir PSA.Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.Stereotactic body radiation therapy for prostate cancer.Single institution's dosimetry and IGRT analysis of prostate SBRT.Potency preservation following stereotactic body radiation therapy for prostate cancer.From radiobiology to technology: what is changing in radiotherapy for prostate cancer.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.

P2860

Q27009327-E00DD13B-4464-47C9-A1EB-81EC08D28512 Q27027563-1C5BDA82-6E56-4013-88E8-E51D3F2E1084 Q30443893-06C2E9D2-B83E-4018-9C33-2D1A320E5FE4 Q33659901-78177CD3-ADE8-47C6-86D8-E275F6E4F6BC Q33851417-47E24669-98DA-481F-A642-8AF79C358536 Q33985573-4820A921-47D1-429B-821E-B561BF686313 Q34413524-5BAAE71B-BFD4-41E4-AB08-F6E6500C6439 Q34487782-0BD5A437-A44A-47FB-BF9C-325CE433A859 Q34500918-DA843032-4B94-479E-B86C-5306E0B5058D Q34660610-7C126E6A-F315-48D9-9332-E99D07759EE1 Q34999092-D2E87F13-26F8-4B93-B62B-11E2F73A97F6 Q35019637-406B0035-69C8-401F-8D8B-29079384099E Q35174871-41BD1502-C141-4BDD-B153-C58998E6E167 Q35233601-D7AD8CC3-CA87-44F9-819E-B2D990902A36 Q35649108-BACC9AC1-83B2-4886-A3B7-81F06555C7C2 Q35816527-F72EAD7F-DD7A-4601-86C3-50A5FA0F86A8 Q35827490-0090B13A-59A2-4AA3-9D38-B3FCE35A65CC Q35947797-D0A71A55-2A88-417B-9A12-77493EFA6B58 Q36009944-06C1FC75-E160-4606-AB44-5BA10553E12A Q36154146-A72E4FFA-74E2-4366-9653-C11CA02B5A1D Q36174829-6E94BA6B-598B-4630-9384-B7101BE08842 Q36426682-D711371E-1880-4969-AD32-D2C6F1AC5690 Q36534796-3402AEB1-0521-4B3C-90A7-BDD96EAECF2A Q36604355-896D6E3D-10DE-4C35-A88A-22C15A357365 Q36711751-30195C13-B618-4CC9-BCDB-2D2CCE1FFC05 Q36722591-C4177625-C008-4765-ABBB-037ABBB2BDB0 Q37025434-FCE1C4E5-3542-4E2B-B8A1-0C6BA282BD77 Q37034249-A1E667FA-424E-4B17-B7C8-ECEC5906F75D Q37143037-6AA13C3E-A543-4799-8E1C-D571750F1667 Q37436220-D5579AAB-ED73-4BC9-A13A-3C5B50F60E49 Q37512971-A72FF2F1-801B-44A6-B544-6D5B75EDE580 Q37551757-D4D201A1-D70A-4F4E-971B-04E86ABEEA8D Q37686861-F3C6BB9B-DD5E-429C-810A-9A7A7A259786 Q37702326-0F9AE029-C14D-48F8-8AC4-4DEC4B35352E Q37932543-6AF64B0F-C42A-4037-817A-35C0DB98F90C Q38137328-39EF8237-CAB9-4786-AF1F-B89564E2A416 Q38158080-55C3148E-FA6A-49B4-95B8-7C98DC2F1BB6 Q38191990-B3299021-2D1D-4BB4-8C49-6A9690D03DE5 Q38226822-ABA9775E-A253-4A46-82B6-58B91E1A43A7 Q38266168-4AFE7E61-76BC-4450-9C0B-B72E78311308

P2860

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

http://www.wikidata.org/entity/Q41775778

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

@en

type

label

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

@en

prefLabel

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

@en

P1433

Q41775778-FF70AB60-37B7-4C6B-95E3-1A63B6F86B21

P1476

Q41775778-9FB41874-16C0-416B-AFDE-C2FF48C37CEC

P2093

Q41775778-1A5F0C22-8B65-4195-85B6-5B415BD4B991

Q41775778-3B93E06E-3120-46C0-9310-D906DC6363EE

P2860

Q41775778-15BED62B-C852-4766-B302-403374AAADE7

Q41775778-1C2D720A-212D-4F00-9E90-13661DFCF053

Q41775778-1C4B79D2-8E0F-4E9F-8C0F-1E1FA3748CBE

Q41775778-24254BC6-B0AE-404E-899D-BC2B156A0F5F

Q41775778-301ACCA5-C358-409B-B440-BFFF8B4F50E6

Q41775778-30685939-E976-4A48-905D-B516DABADA9B

Q41775778-36931418-21B1-4D47-90B3-44DB59260B17

Q41775778-3EB7C0E6-102A-453C-BF77-3A6A963B703A

Q41775778-5563B35F-7CC1-455E-AC1F-EA3DA759263D

Q41775778-63519F7F-3B73-45CC-A1E8-4D17DB4492EC

P2888

Q41775778-7FAC9761-6381-422E-8A8A-160C04437E09

P304

Q41775778-05876B65-54A6-4BD1-945B-780FEE8CD38D

P31

Q41775778-7954A11E-833E-4046-9EF2-106113A97A46

P356

Q41775778-480F7EA2-BFB1-4D30-95FA-97481705BEED

P478

Q41775778-5C3F2249-ACD5-4FF0-8EED-64DB1247F658

P577

Q41775778-8B9704F1-F293-4149-A90E-9EB529029B4C

P6179

Q41775778-EF652D59-D331-42C3-9340-AD9EDCAEA75D

P698

Q41775778-170FCF48-0909-4908-8A36-0A9237BA2FC0

P921

Q41775778-AED5F2AF-ED8C-4436-AF37-FD1566A77CF2

P932

Q41775778-CA20DE0D-0EBC-4132-B4AB-4972E0BC292F

P356

P1433

Radiation Oncology

P1476

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.

@en

P2093

Christopher R King

http://www.w3.org/2001/XMLSchema#string

Debra E Freeman

http://www.w3.org/2001/XMLSchema#string

P2860

Stereotactic body radiotherapy for organ-confined prostate cancer.

CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

Intrafractional motion of the prostate during hypofractionated radiotherapy

Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.

Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer.

Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984).

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

P2888

P304

3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1748-717X-6-3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019169293

http://www.w3.org/2001/XMLSchema#string

P698

21219625

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3022740

http://www.w3.org/2001/XMLSchema#string